GP
Therapeutic Areas
dr-reddys-laboratories Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Semaglutide (Generic) - Obeda | Type 2 Diabetes | Launched |
| Semaglutide (Oral Generic) | Type 2 Diabetes, Obesity | Pre-launch |
| Toripalimab | Recurrent/Metastatic Nasopharyngeal Carcinoma | Launched |
| Bevacizumab Biosimilar | Various Cancers (Colorectal, Lung, etc.) | Launched |
| Lenacapavir | HIV-1 Infection | Partnership |
| CAR-T Cell Therapy | Relapsed/Refractory Multiple Myeloma | Discovery/Development |
| Injectable Contraceptive | Women's Health / Family Planning | Development |
| Beyfortus® (Nirsevimab) | RSV Prevention in Infants | Launched |
Leadership Team at dr-reddys-laboratories
EI
Erez Israeli
Chief Executive Officer
MR
M.V. Ramana
CEO, Branded Markets
DS
Deepak Sapra
CEO, API & Services
DM
Dr. Murali Ramachandra
Chief Executive Officer, Aurigene Oncology
KV
Krishna Venkatesh
Global Head of Quality and Pharmacovigilance
DK
Dr. Kallam Anji Reddy
Founder